Overview |
bs-3331R-Cy5.5 |
PFK2 (Ser467) Polyclonal Antibody, Cy5.5 Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
This phosphorylated site is homologous to that of Ser467 in Mouse and Ser496 in Rat. |
Human, Mouse, Rat |
Cow, Pig, Horse, Chicken, Rabbit |
Specifications |
Cy5.5 |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human PFK2 around the phosphorylation site of Ser467 |
Ser467 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
5209 |
Q16875 |
Cytoplasm, Nucleus |
PFK2; IPFK2; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; 6PF-2-K/Fru-2,6-P2ase 3; PFK/FBPase 3; 6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme; Renal carcinoma antigen NY-REN-56; iPFK-2; PFKFB3 |
6 Phosphofructo 2 Kinase plays a role in the synthesis and degradation of fructose 2,6-bisphosphate. Fructose-2,6-bisphosphate acts as an allosteric regulator of 6-phosphofructo-1-kinase (PFK1), which catalyses a key step in the glycoytic pathway. Glycolytic flux is key to tumour growth, and small molecule inhibition of 6 Phosphofructo 2 Kinase suppresses both glycolytic flux and tumour growth. Several lines of evidence suggest that 6 Phosphofructo 2 Kinase is also involved in obesity. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |